Australia. (Levy F et al. J Am Acad Child Adolesc Psychiatry June 1997;36:737-744). ADHD may be explained as an inherited trait with liability and expression throughout the population, a deviance from an acceptable norm, and not restricted to an arbitrary number of symptoms or DSM criteria. The need for treatment including medication is relative, and dependent on multiple factors.

**METHYLPHENIDATE TREATMENT AND HOME BEHAVIOR**

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate are reported in a study of 91 children receiving MPH (titrated to 0.7 mg/kg twice a day) or placebo for 4 months at the Hospital for Sick Children, Toronto, Canada. Symptoms of ADHD and comorbid oppositional behavior improved while at school, but not on returning home. Side effects were observed by the parents, not by teachers, and necessitated MPH withdrawal in 10%; these included sadness, behavioral deterioration, irritability, withdrawal, lethargy, violent behavior, and mild mania. Anorexia, loss of weight gain (without effect on growth), and stomachache were the most common physiological side effects, and withdrawal, sadness, and crying, the most common affective side effects during MPH treatment. (Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry June 1997;36:754-763). (Reprints: Dr Schachar, Child Psychiatry Research Unit, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8).

COMMENT. Methylphenidate administered twice daily benefits behavior and attention of ADHD children in the classroom but not in the home. Three times daily schedule of doses might facilitate completion of home work assignments and lead to improved parent-child relations. (see Ped Neur Briefs Nov 1996;10:82, for review of MPH dosing schedules and a report by Stein MA, Roizen NJ et al).

**DEGENERATIVE DISORDERS**

**GENETICS OF JUVENILE SPINAL MUSCULAR ATROPHY**

A 20-year-old female with difficulties in running and climbing stairs since age 10 and suspected of having spinal muscular atrophy (SMA) type III (Kugelberg-Welander disease) was diagnosed with GM2 gangliosidosis at the Department of Human Genetics, Sackler Faculty of Medicine, Tel Aviv University, and Sapir Medical Center, Kfar-Sava, Israel. Amyotrophy extended to the middle of the thighs in the lower limbs and had a distal glove distribution in the upper limbs. Deep tendon reflexes were present except for the ankle jerks. The survival motor neuron (SMN) gene, lacking in SMA, showed no deletion. Biochemical studies showed increased accumulation of GM2 ganglioside and deficiency of hexosaminidase A (Hex A) activity in fibroblasts. In the HEXA gene, two mutations occurred, and the patient was a compound heterozygote, with each allele containing a different mutation. (Navon R, Khosravi R, Melki J et al. Juvenile-onset spinal muscular atrophy caused by compound heterozygosity for mutations in the HEXA gene. Ann Neurol May 1997;41:631-638). Respond: Prof Navon, Molecular Genetics, Sapir Medical Center, Kfar-Sava 44281, Israel).

COMMENT. Progressive spinal muscular atrophy (SMA) type III
(Kugelberg-Welander disease) and GM2 gangliosidosis are both autosomal recessive in inheritance. Molecular studies on a proband thought to have SMA have uncovered a GM2 gangliosidosis as the cause of the progressive amytrophy. The SMA gene showed no deletion while the HEXA gene had two mutations. At the onset of GM2 gangliosidosis, clinical manifestations are variable and the differential diagnosis may include SMA or Friedreich ataxia.

**GENETICS OF FRIEDREICH ATAXIA**

Genotype-phenotype correlations in a group of 100 patients with typical Friedreich ataxia (FRDA), and in three smaller clinically atypical groups (Arcadian FRDA, late-onset FRDA (LOFA), and FRDA with retained reflexes (FARR)), were studied at the Centre de Recherche Louis-Charles Simard, Service de Genetique Medicale, Service de Neurologie, Hopital Sainte-Justine, Departments of Genetics and Medicine, McGill University, Montreal General Hospital, and other centers. Almost all FRDA patients carry a GAA triplet repeat expansion on chromosome 9, despite phenotypic variation. Larger expansions lead to earlier onset and more severe disease. Arcadian FRDA and FARR were unrelated to expansion sizes. (Montermini L, Richter A, Morgan K et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol May 1997;41:675-682). (Respond: Dr Massimo Pandolfo, Centre de Recherche Louis-Charles Simard, Pavillon De Seve, 1560 rue Sherbrooke est, Montreal, Quebec, Canada H2L 4M1).

**COMMENT.** Testing for the GAA expansion is essential for the molecular diagnosis of the various forms of FRDA, and particularly atypical cases of late-onset, those with retained reflexes, and lack of the characteristic hypertrophic cardiomyopathy.

**LEUKODYSTROPHY AND OVARIAN DYSGENESIS**

Clinical, biochemical, pathological, and spectroscopic findings in 4 women, aged 15 to 29 years, with leukodystrophy and primary ovarian dysgenesis, are reported from the National Institutes of Neurological Disease, and Child Health and Development, Bethesda, MD. Neurologic evaluations revealed cognitive impairment in 3 (IQs 52, 60, 77), ataxia at age 10 in one, speech delay in one, febrile seizures in one, neurologic deterioration at ages 6-10, 17, and 24, mild clumsiness, cerebellar and pyramidal signs, optic atrophy, dysarthria, and facial weakness. Puberty was delayed in 2, and 2 had amenorrhea, with primary gonadal insufficiency and normal hypothalamic-hypophyseal axis. MRI showed diffuse white matter disease, with frontal cortical atrophy. Proton MRS showed reduction of choline-containing compounds and N-acetylaspartate in the white matter. (Schiffmann R, Tedeschi G, Kinkel RP et al. Leukodystrophy in patients with ovarian dysgenesis. Ann Neurol May 1997;41:654-661). (Respond: Dr Schiffmann, NIH, Bldg 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892).

**COMMENT.** A novel syndrome of leukodystrophy and primary ovarian dysgenesis of unknown cause is reported in 4 young women who presented with variable neurological impairments in the first or second decades. Chromosomes were normal, and Turner's syndrome was ruled out. Known causes for leukodystrophy were also excluded. The molecular basis for the syndrome remains to be determined.